Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Biotechnology

Healthcare
$13.33 -1.34%

-$0.12 today

Market cap
$470.62M
Beta
1.08
P/E (TTM)
-36.3
EPS (TTM)
-$0.24
52W Low $5.65High $10.45

Volume 0.59M

Average 0.26M

FENC Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Fennec Pharmaceuticals Inc.NASDAQ: FENC

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 77.2% from a year ago

Cash & equivalents stood at $40.18M at the end of Q1 FY2026, up 77.2% from a year earlier and up 9.4% from the prior quarter. Over 3 fiscal years it compounded at +15.6% a year.

Context

  • Cash & equivalents amounted to 55.9% of total assets at the end of Q1 FY2026, up 7.1 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +77.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$40.18M+9.4% QoQ
Last fiscal yearDec 2025
$36.72M+37.9% YoY
Year agoMar 2025
$22.68M+77.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+77.2%——
1 year+37.9%——
3-year CAGR+15.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
36.72M USD
Year-over-year change
+37.9%
4-year CAGR
+14.9%

Cash & Equivalents vs competitors

How FENC compares with its peers on the latest reported figures

  • FENC's Mar 2026 cash & equivalents of $40.18M is the 4th highest of the 11 companies compared; the peer median is $29.22M.
  • Its year-over-year change of +77.2% is the 3rd highest of 11, against a peer median of -44.0%.
  • Cash & equivalents amounts to 55.9% of total assets for FENC, versus a peer median of 23.8%.
FENC Competitors Peer median
Cash & Equivalents for FENC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RNACCartesian Therapeutics, Inc.Mar 2026$118.64M -34.2%+5.5%41.1%
AARDAardvark Therapeutics, Inc. Common StockMar 2026$62.44M +135.6%+44.6%63.3%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$58.69M +113.8%+48.2%40.2%
FENCFennec Pharmaceuticals Inc.Mar 2026$40.18M +77.2%+15.6%55.9%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$34.93M -42.0%-9.8%11.1%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026$30.07M -69.4%-15.1%22.6%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$28.37M +54.6%+20.6%28.2%
AVTXAvalo Therapeutics, Inc.Mar 2026$24.99M -80.0%+6.4%25.0%
PRLDPrelude Therapeutics IncorporatedMar 2026$21.76M -46.0%+4.8%18.2%
NAUTNautilus Biotechnology, Inc.Mar 2026$14.63M -56.0%-52.4%8.2%
CRBUCaribou Biosciences, Inc.Mar 2026$12.06M -59.0%-40.4%8.1%
Peer median (excluding FENC) $29.22M-44.0%+5.2%23.8%

Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents21.1M23.77M13.27M26.63M36.72M
Short-term Investments00000
Net Receivables01.55M8.81M12.88M23.18M
Inventory0576K2.16M1.06M1.56M
Other Current Assets253K63K44K466K1.37M
Total Current Assets22.39M26.73M26.86M44.12M66.56M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00002.79M
Tax Assets00000
Other Non-current Assets27K211K6K822K710.62K
Total Non-current Assets27K211K6K822K3.5M
Total Assets22.41M26.94M26.86M44.95M70.07M
Account Payables777K2.39M3.78M3.24M4.63M
Short-term Debt00000
Tax Payables00000
Deferred Revenue0000247.55K
Other Current Liabilities000248K(10.25K)
Total Current Liabilities1.65M4.61M7.55M6.92M10.5M
Long-term Debt4.99M24.9M30.93M19.34M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000024.56M
Other Non-current Liabilities00024.56M0
Total Non-current Liabilities4.99M24.9M30.93M43.9M24.52M
Total Liabilities6.64M29.51M38.49M50.82M35.02M
Common Stock140.8M142.59M144.31M145.61M189.56M
Retained Earnings(179.49M)(203.2M)(219.25M)(219.68M)(229.36M)
Accumulated OCI1.24M1.24M1.24M1.24M1.24M
Other Stockholders Equity025.75K010
Minority Interest00000
Total Equity15.77M(2.57M)(11.62M)(5.87M)35.05M
Total Debt4.99M24.9M30.95M19.34M0
Net Debt(16.11M)1.13M17.69M(7.29M)(36.72M)

Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Intrinsic Alpha fair value

Locked

Current Price

$13.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.